News & Updates

A real-world study during Hong Kong’s Omicron BA.2.2 wave has shown that viral burden rebound is uncommon in hospitalized COVID-19 patients not requiring supplemental oxygen on admission, regardless of whether they were treated with nirmatrelvir/ritonavir or molnupiravir. However, immunocompromised patients, regardless of oral antiviral use, are more likely to have viral burden rebound.

Mirabegron appears to be as good as vibegron in the treatment of overactive bladder (OAB) in postmenopausal women, with both drugs helping improve symptoms and the parameters of voiding diary, according to a study.